Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Social media

Amy Taylor

BSc (Hons) MSc (Res)


Operational Lead NDS SITU

I am an Operational Lead for NDS SITU, overseeing a portfolio of surgical clinical trials that cover areas as diverse as melanoma and brain tumours to chronic rhinosinusitis and upper GI surgery. I have worked in research at pre-clinical and clinical stages since 2002, developing extensive translational and transferable skills from each role.

As an operational lead for the unit, I am involved in the development of new grant applications, initial application and assessment stages and then oversee the set-up and implementation of the trial post-award. I provide ongoing management and guidance to trials at all stages, assisting the trial managers and clinical teams as needed. I am responsible for helping the trial managers meet their trial milestones and work closely with the trial CIs to ensure trials are delivered to a high standard.

Prior to this, I was Clinical Trial Manager for the FUTURE-GB trial (Functional and Ultrasound Guided Resection of Glioblastoma), in SITU(NDS). I have also worked in SITU (NDORMS) as a Clinical Trial Manager for NINJA - a large paediatric plastic surgery trial, and also on the feasibility study, SPINOUT-F.

I was a research coordinator for OxAAA, a large vascular study in NDS, and before that, worked in behavioural neuroscience research for 13 years across various Oxford University departments, gaining extensive experience in lab work, handling and analysis of large datasets and regulatory compliance processes. I obtained my MSc (Res) from the University of Oxford looking at the role of excitatory amino acid receptor subtypes in hippocampal-dependent learning and memory.